MedTrace Logo

Subcutaneous Immunoglobulin Treatment for Multifocal Motor Neuropathy

NCT00268788 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2008-02-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of subcutaneous administration of immunoglobulin compared to intravenous treatment, for multifocal motor neuropathy

NB. ONLY RECRUITING FROM DENMARK

Conditions

  • Multifocal Motor Neuropathy

Interventions

DRUG

Subcutaneous immunoglobulin

Individually dosed, given twice a week.

DRUG

Intravenous immunoglobulin

Individual dose and frequency

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Henning Andersen, MD, DMSc · Aarhus University Hospital

  • Johannes Jakobsen, Professor · Aarhus University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00268788 on ClinicalTrials.gov